CytomX Therapeutics Q2 EPS $(0.02) Beats $(0.20) Estimate, Sales $24.72M Beat $13.88M Estimate
Portfolio Pulse from Benzinga Newsdesk
CytomX Therapeutics reported Q2 earnings per share (EPS) of $(0.02), beating the analyst consensus estimate of $(0.20) by 90%. This is a 94.59% increase over losses from the same period last year. The company also reported quarterly sales of $24.72 million, beating the analyst consensus estimate of $13.88 million by 78.13%. This is a 36.11% increase over sales from the same period last year.
August 08, 2023 | 9:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CytomX Therapeutics reported better than expected Q2 earnings and sales, which could positively impact the stock.
CytomX Therapeutics reported Q2 earnings and sales that beat analyst estimates. This positive financial performance could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100